kabutan

Noile-Immune Biotech Inc.(4893) Summary

4893
TSE Growth
Noile-Immune Biotech Inc.
143
JPY
0
(0.00%)
Jan 29, 3:10 pm JST
0.93
USD
Jan 29, 1:10 am EST
Result
PTS
outside of trading hours
143
Jan 29, 2:57 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.51
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
143 JPY 0.93 USD
Previous Close Jan 28
143 JPY 0.93 USD
High Jan 29, 1:04 pm
145 JPY 0.94 USD
Low Jan 29, 9:10 am
140 JPY 0.91 USD
Volume
140,300
Trading Value
0.02B JPY 0.13M USD
VWAP
142.91 JPY 0.93 USD
Minimum Trading Value
14,300 JPY 93 USD
Market Cap
6.19B JPY 0.04B USD
Number of Trades
87
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
233
1-Year High Jul 2, 2025
8,956
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 273,700 991,500 3.62
Jan 16, 2026 235,500 1,030,600 4.38
Jan 9, 2026 225,600 989,500 4.39
Dec 26, 2025 201,700 1,012,800 5.02
Dec 19, 2025 149,000 973,600 6.53
Company Profile
Noile-Immune Biotech Inc. engages in the development of novel immunotherapies utilizing CAR-T cells for cancer treatment.
Sector
Pharmaceuticals
Noile-Immune Biotech Inc. focuses on developing novel immunotherapies utilizing CAR-T cells for cancer treatment. The company aims to develop effective CAR-T cell therapies for solid tumors using its proprietary PRIME technology. PRIME technology is a platform technology that can be applied to regenerative medicine, with the potential to achieve superior cancer treatment effects by activating immune cells within the patient's body. It promotes the infiltration and activation of immune cells into solid tumor tissues. Noile-Immune Biotech pursues two business models: in-house drug discovery and collaborative pipelines, with multiple pipelines in progress. The company is also conducting clinical trials targeting solid tumors, exploring new possibilities in cancer immunotherapy.